HBV Prevention and Treatment in Countries of Central Asia and the Caucasus

Amerzhanov, Daulet; Suleimenova, Indira; Davlidova, Salima; Nugmanova, Zhamilya; Ali, Sajid

doi:10.3390/v12101112

Cited by 9 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies of the prevalence of viral hepatitis in Central Asian countries showed a decrease in the prevalence of viral hepatitis B in Kazakhstan [31]. We believe that this was due to the study of the prevalence of viral hepatitis in a specific cohort and not in the entire population of the country.…”

Section: Discussionmentioning

confidence: 78%

Prevalence of Viral Hepatitis B, C, and D in Kazakhstan

Jumabayeva

Nersesov

Kulzhanov

et al. 2022

The Scientific World Journal

View full text Add to dashboard Cite

Background. Viral hepatitis is a major burden for the healthcare system worldwide. Up to date, a comprehensive analysis of the prevalence of viral hepatitis in Kazakhstan and Central Asia has not been carried out yet. Our epidemiological study aimed at investigating the frequency and spread of viral hepatitis B, C, and D depending on age and sex in Kazakhstan (5-year period). Materials and Methods. We utilized the data from the primary registration of the incidence of hepatitis B, C, and D in 18 regions of Kazakhstan (period: from 2015 to 2020). Age indicators, gender, and territorial characteristics of registered cases were determined and analysed. The data were obtained from the state information system “Electronic Register of Dispensary Patients”, based on the International Classification of Diseases-10 for coding diseases. Results. During the period studied, 268 975 cases of hepatitis B, C, and D were detected in Kazakhstan. Hepatitis B was registered in n = 109 734 cases. In women, the incidence rate was 40.6% of all cases (n = 44545), and in men it was 59.4% (n = 65189) of all cases ( p ≤ 0.01 ). Hepatitis D was detected in 8 656 cases, of which 58.3% (n = 5049) were in men and 41.7% (n = 3607) in women ( p ≤ 0.01 ). Hepatitis C was registered in n = 159 585 cases. The rate was higher in the male population (54.6%; n = 82 203) compared to women 45.4% (n = 68382) ( p ≤ 0.01 ). In 2020 (in comparison with 2015), there was a significant increase in the incidence of hepatitis D by 68.3%, hepatitis B by 49.8%, and hepatitis C by 46.4%. The largest prevalence of hepatitis D was recorded in 2016 which is 22.3% higher compared to 2020. A significant increase in hepatitis C was recorded in 2019 compared to 2015, where indicators were 49.2% higher. Conclusion. An analysis of the prevalence of hepatitis B, C, and D showed an increase in new cases in Kazakhstan. These findings indicate the need to develop effective preventive measures and screening strategies among people in a high-risk group. The results of the study can be used for the development of a national program to combat the spread of viral hepatitis.

show abstract

Section: Discussionmentioning

confidence: 78%

Prevalence of Viral Hepatitis B, C, and D in Kazakhstan

Jumabayeva

Nersesov

Kulzhanov

et al. 2022

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…In Southeast Asia, the estimation of birth‐dose vaccination coverage is only 34%, while three‐dose vaccination reaches 89% in 2019 74 . In Central Asia, the coverage of birth‐dose and three‐dose is 95%–99% respectively, which is an impressive achievement among developing countries 75 . With the availability and recommendation of neonatal vaccination, HBV vaccine coverage has been increasing in the past 5 years and more people in low‐income regions will be covered in the future.…”

Section: Prevention and Surveillancementioning

confidence: 99%

“…74 In Central Asia, the coverage of birth-dose and three-dose is 95%-99% respectively, which is an impressive achievement among developing countries. 75 With the availability and recommendation of neonatal vaccination,…”

Section: Preventing Hbv Infectionmentioning

confidence: 99%

Changing epidemiology of hepatocellular carcinoma in Asia

Zhang

Cheng

Zhang

et al. 2022

Liver International

177

View full text Add to dashboard Cite

Primary liver cancer is the sixth most frequently diagnosed cancer and the third most lethal cancer, with an estimation of 906 000 new cases and 830 000 deaths worldwide. 1 The highest incidence rates of primary liver cancer are observed in Asian countries, where primary liver cancer is the fifth most common cancer and the second leading cause of cancer mortality. However, great variation is reported within specific geographic regions within Asia.According to GLOBOCAN 2020, Mongolia is reported to have the highest age-standardized rate (ASR) of both incidence and mortality (85.6 and 80.6/100 000), while China still comprises the

show abstract

“…Review on HBV prevention and treatment in Central Asian countries reported the estimated prevalence of HBV infection as 3.4%. 12 According to the recent systematic review on prevalence of HIV, HCV and HBV in Central Asian countries, the highest prevalence of HCV was reported in Kazakhstan with 90.1% among Intravenous Drug Users (IVDU); and HBV among IVDU to be 74.2% and 85.3% in two regions of the country. 13 Nationwide universal vaccination program was implemented in 1998 and is expected to decrease the burden of HBV infection in future decades.…”

Section: Introductionmentioning

confidence: 99%

Epidemiological Characteristics of Chronic Viral Hepatitis in Kazakhstan: Data from Unified Nationwide Electronic Healthcare System 2014–2019

Ashimkhanova¹,

Syssoyev²,

Gusmanov³

et al. 2022

IDR

View full text Add to dashboard Cite

Background: Viral hepatitis is the leading cause of hepatic cirrhosis and liver-related mortality, yet there are no countrywide epidemiological studies available to date in Kazakhstan. The aim of the study was to perform an estimation of mortality, prevalence and incidence of Hepatitis B and C infections and liver-related complications. Methods: Using centralized healthcare data from the Unified National Electronic Health System (UNEHS) for the period 2014-2019, a total of 82,700 registered patients with chronic viral hepatitis B (HBV), C (HCV) and D (HDV) have been extracted based on ICD −10 codes. Crude rates of incidence, prevalence and mortality, as well as age-, sex-and year-specific rates of incidence and mortality per 100,000 population were estimated. Unadjusted and adjusted hazard ratios were estimated using Cox proportional hazards regression modeling. Results: For the total number of 82,700 patients, 56.6% were represented by chronic HCV infection and 43.4% by HBV infection. The prevalence of coinfection was 10% for HBV+HDV and 3.5% for HBV+HCV. Both HBV and HCV were more prevalent among female patients (56%) and among Kazakh ethnic group (64.8%). Males with HBV had a higher probability of death than females; this trend was stronger among male patients with HCV. Russian ethnic groups infected with HBV had a higher risk of death compared to Kazakh and other ethnic groups. Whereas in HCV-infected patients, Russian ethnic group and other ethnic group had similar risk for death, but higher compared to Kazakhs. Conclusion: During the 2014-2019 period, prevalence, incidence and mortality from chronic HBV and HCV infections increased. Despite the disproportionately higher infection rate among females with chronic viral hepatitis, all-cause mortality was more than twofold higher among males. Higher death rates in Russian ethnic group compared to other ethnicities need to be evaluated in further studies for other confounding factors and associated comorbidities in this group.

show abstract

HBV Prevention and Treatment in Countries of Central Asia and the Caucasus

Cited by 9 publications

References 7 publications

Prevalence of Viral Hepatitis B, C, and D in Kazakhstan

Prevalence of Viral Hepatitis B, C, and D in Kazakhstan

Changing epidemiology of hepatocellular carcinoma in Asia

Epidemiological Characteristics of Chronic Viral Hepatitis in Kazakhstan: Data from Unified Nationwide Electronic Healthcare System 2014–2019

Contact Info

Product

Resources

About